Lexeo (LXEO) - Forward P/S Multiple
The forward price-to-sales ratio demonstrates the business resilience within an autonomous product cycle, where the metric is maintained at . Lexeo Therapeutics (LXEO) focuses on developing genetic drugs for the treatment of heart and brain pathologies by investing in R&D. The company's success depends on the safety of gene delivery and regulatory approval of new therapies for cardiovascular diseases.
Metric breakdowns and analytics for lexeotx.com (LXEO)
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Lexeo Therapeutics|LXEO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Lexeo Therapeutics, Inc.|LXEO - Company Cumulative Indebtedness|Debts to Book Capitalization Lexeo Therapeutics, Inc.|LXEO - Long-Term Debt Volume|Company Short-Term Debts Lexeo Therapeutics|Quick Liquidity lexeotx.com
- business earnings and investment ratios data:
LXEO - Net Financial Result|Expected Profit Lexeo Therapeutics|LXEO - Price to Earnings Ratio|Projected Price to Earnings Lexeo Therapeutics, Inc.|LXEO - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Lexeo Therapeutics, Inc.|LXEO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Lexeo Therapeutics|LXEO - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth lexeotx.com|LXEO - Earnings per share growth this year|Net earnings per share growth forecast for next year Lexeo Therapeutics
- sales volume and revenue information:
General company analysis:Lexeo LXEO
Capital is seeking to decouple resilient assets from speculative ones, utilizing the market capitalization-to-projected revenue ratio to determine fair business value. As Lexeo Therapeutics (LXEO) competes aggressively against biotech behemoths for a limited patient pool, the forward P/S multiple reflects market confidence in the therapy's commercial success, where any increase in the ratio elevates the risk of a sharp correction should certification be delayed.
Analysis of competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|RGEN - Forward P/S Multiple|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CRSP (crisprtx.com)|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Forward P/S Multiple Sarepta Corp (SRPT)|Twist Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke Therapeutics Inc STOK|BLFS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|Price-to-Projected Revenue Ratio TSHA (Taysha Gene Therapies Inc)|uniQure Corp - Forward Price-to-Revenue Multiple|MGTX: Market Cap to Projected Revenue|REGENXBIO Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio solidbio.com|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Pacific Biosciences of California, Inc. (PACB)|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Corp)|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple KRRO (Korro Bio)|Forward P/S Multiple Editas Medicine Inc EDIT|SLN - Price-to-Projected Revenue Ratio|PRQR: Price-to-Projected Revenue Ratio|CDXS: Forward P/S Multiple|Market Cap to Future Revenue Ratio sangamo.com (SGMO)|Forward Price-to-Revenue Multiple NAUT|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Forward P/S Multiple DTIL|GBIO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Exicure Inc. (XCUR) - Market Cap to Future Revenue Ratio|IMNN: Forward Price-to-Revenue Multiple|Forward Price to Sales PHIO (Phio Pharmaceuticals)|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|RNAZ: Price to Expected Revenue Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|APDN: Forward Price to Sales|Forward P/S Multiple BLUE|IPA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omega OMGA|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS - Forward P/S Multiple|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Forward P/S Multiple
